Merck to acquire Prometheus Biosciences, maker of autoimmune drugs, for $10.8 billion
Merck said Sunday that it will acquire Prometheus Biosciences for $10.8 billion, adding a pipeline of experimental drugs to treat immune-related diseases.
The deal values Prometheus at $200 per share, or a 75% premium to Friday’s closing stock price.
